Search clinical trials for: Denosumab Injection

Total 9855 results

Shanghai Biomabs Pharmaceutical Co., Ltd.

Recruiting

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

Postmenopausal Osteoporosis

China
Wuhan Union Hospital, China

Not yet recruiting

Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes

Sarcopenia | Osteoporosis | Denosumab

China
Ole Lander Svendsen

Recruiting

The DENOCHARCOT Trial

Diabetes Mellitus | Charcot Foot

Denmark
Albert Einstein Healthcare Network
Amgen

Withdrawn

A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.

Osteoporosis
Qilu Pharmaceutical Co., Ltd.

Unknown

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Bone Metastases

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Bone Metastases

China
Qilu Pharmaceutical Co., Ltd.

Unknown

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

Healthy People

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Healthy

China
Qilu Pharmaceutical Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Healthy People

China
Kyoto Prefectural University of Medicine

Active, not recruiting

Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

Breast Cancer

Japan
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

Postmenopausal Osteoporosis

China
Turku University Hospital
Amgen

Completed

Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women (ProliaHip)

Hip Osteoarthritis

Finland
University Hospital, Montpellier
University Hospital, Rouen; University Hospital, Lille; Nantes University Hospital and other collaborators

Terminated

Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa (DIBLAN)

Anorexia Nervosa

France
Felicia Cosman, MD
Crozer-Keystone Health System; Radius Health, Inc.

Recruiting

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Osteoporosis, Postmenopausal

United States
Shenzhen People's Hospital

Completed

Denosumab vs Zoledronate After Vertebroplasty

Denosumab Allergy | Zoledronic Acid Allergy

China
Massachusetts General Hospital
Amgen

Completed

Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study

Anorexia Nervosa | Bone Loss | Eating Disorder | Bone Density | Atypical Anorexia Nervosa

United States
Massachusetts General Hospital

Completed

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

Postmenopausal Osteoporosis

United States
Kunming Pharmaceuticals, Inc.

Unknown

Comparing of the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults.

Healthy
Afyonkarahisar Health Sciences University

Completed

The Efficacy of PRP Injection in the Treatment of Rotator Cuff Syndrome (PRP)

Musculoskeletal Diseases | Shoulder Pain | Rotator Cuff Tendinopathy | Rotator Cuff Syndrome

Turkey
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

Poland
Amgen

Completed

Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

Osteoporosis | Osteopenia | Low Bone Mineral Density | Low Bone Mass | Males With Osteoporosis
GlaxoSmithKline

Completed

A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

Osteoporosis, Postmenopausal

Korea, Republic of
Amgen

Completed

Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004

Giant Cell Tumor of Bone

Australia, France, United States, Spain, Italy, Poland, Sweden, United Kingdom
Amgen

Completed

Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product

Healthy Volunteer

United States
Borstkanker Onderzoek Groep
Amgen

Withdrawn

Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer (PERIDENO)

Breast Neoplasms

Netherlands
Amgen

Completed

A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

United States, Denmark, Poland, Canada
Luye Pharma Group Ltd.
Shan Dong Boan Biotechnology Co., Ltd

Active, not recruiting

A Study to Evaluate LY06006 and Prolia in Healthy Adults

Healthy Adults

China
Swiss Group for Clinical Cancer Research

Active, not recruiting

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Metastatic Breast Cancer | Bone Metastases | Metastatic Prostate Cancer

Switzerland, Germany, Austria
Luye Pharma Group Ltd.
Parexel

Completed

A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection

Healthy

Germany
GlaxoSmithKline

Completed

China HVT Safety, PK, PD

Osteoporosis

China
Luye Pharma Group Ltd.
Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)

Unknown

A Study to Evaluate LY01011 and Xgeva® in Healthy Adults

Healthy Adults
National Cancer Institute (NCI)

Terminated

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Ovarian Carcinoma

United States, Israel
National Institute of Dental and Craniofacial Research...

Recruiting

Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia

Fibrous Dysplasia

United States
Shanghai JMT-Bio Inc.

Completed

A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone

Giant Cell Tumor of Bone

China
GlaxoSmithKline

Completed

A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

Osteoporosis, Postmenopausal

India
Amgen

Completed

Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab

Relapsed or Plateau-Phase Multiple Myeloma
Amgen

Completed

A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density

Osteoporosis | Osteopenia | Low Bone Mineral Density
Amgen

Completed

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Lymphoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Non-Small Cell Lung Cancer | Lung Cancer | Metastatic Cancer | Colon Cancer | Thyroid Cancer | Renal Cancer | Parathyroid Neoplasms | Endocrine Cancer | Hypercalcemia of Malignancy

United States, Italy, France, Canada, Poland
RenJi Hospital
Shanghai JMT-Bio Inc.

Not yet recruiting

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Multiple Myeloma | Bone Diseases
Indiana University

Withdrawn

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders

Vasculitis | Osteoporosis | Dermatomyositis | Juvenile Rheumatoid Arthritis | Glucocorticoid-induced Osteoporosis | Polyarthritis | Systemic Lupus Erythematosis

United States
HealthEast Care System
Amgen

Completed

Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index

Osteoporosis | Bone Fracture

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma

United States, Canada, Puerto Rico
Australian and New Zealand Intensive Care Research...

Recruiting

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (BoneZone)

Critical Illness | Osteoporosis

Australia, New Zealand
Alvotech Swiss AG

Completed

AVT03 With Prolia in Healthy Male Subjects

Healthy Male Subjects

New Zealand
Nigde Omer Halisdemir University

Completed

Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients

Postmenopausal Osteoporosis

Turkey
Rudolf Wuethrich

Completed

Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients (POSTOP)

Chronic Kidney Disease | Osteoporosis

Switzerland
NYU Langone Health

Completed

Presurgical Trial of Denosumab in Breast Cancer

Breast Cancer

United States
Amgen

Completed

Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France (PILOTE)

Post Menopausal Osteoporosis

France
Seoul National University Bundang Hospital

Unknown

Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled Trial

Spine Deformity

Korea, Republic of
Amgen

Completed

A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab

Osteoporosis | Postmenopausal Osteoporosis | Low Bone Mineral Density | Low Bone Mass

Search clinical trials for: Denosumab Injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations